Hillstream BioPharma is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for the prevention and treatment of metastatic solid tumors. The company’s proprietary platform harnesses platelet biology to target and deliver therapeutic agents directly to the tumor microenvironment, with the goal of enhancing anti-tumor efficacy while minimizing off-target toxicity. Through its research pipeline, Hillstream advances both antibody-based and small molecule candidates designed to disrupt key interactions between tumor cells, platelets and immune effectors.
The company’s lead program, HIL-101, is a bispecific antibody that binds P-selectin on activated platelets and a tumor-associated antigen to facilitate localized immune activation. In parallel, Hillstream is developing HIL-102, a small molecule inhibitor aimed at blocking platelet-driven immunosuppression within metastatic niches. Both candidates have shown promising preclinical activity in models of breast, lung and colorectal cancer, and the company is preparing to initiate first-in-human studies under its investigational new drug applications.
Founded in 2015 and headquartered in Suzhou, China, Hillstream BioPharma also maintains a research hub in Houston, Texas, to support its translational activities and global clinical strategy. The company collaborates with leading academic institutions and contract research organizations across North America and Asia, leveraging a network of partnerships to accelerate its development timeline. Hillstream’s cross-border approach aims to bring its platelet-targeting technology to patients worldwide.
Hillstream BioPharma is led by Chairman and Chief Executive Officer Dr. Paul Hao, a veteran of the oncology drug development field, and Chief Scientific Officer Dr. Lina Chen, who brings extensive expertise in immuno-oncology and translational research. The management team is complemented by industry-seasoned executives in regulatory affairs, clinical operations and manufacturing, positioning the company to advance its innovative portfolio through key clinical milestones.
AI Generated. May Contain Errors.
